Cochrane · systematic review · CD013316
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
McAleenan, A, Kelly, C, Spiga, F, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 70%Low 2 · 20%Moderate 1 · 10%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Methods for measuring MGMT promoter methylation status
Population: people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
MSP compared with IHC | no estimate extracted | 7 studies · 913 participants | Moderate Downgraded: imprecision |
PSQ compared with IHC | no estimate extracted | 5 studies · 871 participants | Low Downgraded: imprecision, indirectness |
PSQ compared with MSP | no estimate extracted | 9 studies · 1119 participants | Low Downgraded: imprecision, indirectness |
Variants of PSQ | no estimate extracted | 11 studies · 876 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
qMSP (against MSP or PSQ) | no estimate extracted | 7 studies · 765 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Bead array (against MSP or PSQ) | no estimate extracted | 2 studies · 81 participants | Very low Downgraded: imprecision, inconsistency, indirectness |
PCR‐mRNA (against MSP or PSQ) | no estimate extracted | 2 studies · 148 participants | Very low Downgraded: imprecision, inconsistency, indirectness |
MS‐MLPA (against MSP or PSQ) | no estimate extracted | 1 study · 48 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
PCR‐HRM (against MSP or PSQ) | no estimate extracted | 3 studies · 309 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Other techniques (against MSP or PSQ) | no estimate extracted | 7 studies · 1209 participants | Very low Downgraded: imprecision, inconsistency, indirectness |